Orbimed Advisors LLC Esperion Therapeutics, Inc. Transaction History
Orbimed Advisors LLC
- $4.44 Billion
- Q1 2024
A detailed history of Orbimed Advisors LLC transactions in Esperion Therapeutics, Inc. stock. As of the latest transaction made, Orbimed Advisors LLC holds 13,708,731 shares of ESPR stock, worth $28.7 Million. This represents 0.83% of its overall portfolio holdings.
Number of Shares
13,708,731Holding current value
$28.7 Million% of portfolio
0.83%Shares
1 transactions
Others Institutions Holding ESPR
# of Institutions
174Shares Held
125MCall Options Held
2.08MPut Options Held
1.01M-
Bellevue Group Ag Kuesnacht, V89.94MShares$20.8 Million0.42% of portfolio
-
Wasatch Advisors Inc Salt Lake City, UT9.13MShares$19.1 Million0.13% of portfolio
-
Vanguard Group Inc Valley Forge, PA8.83MShares$18.4 Million0.0% of portfolio
-
Great Point Partners LLC Greenwich, CT8MShares$16.7 Million5.25% of portfolio
-
Woodline Partners LP San Francisco, CA7.92MShares$16.6 Million0.2% of portfolio
About Esperion Therapeutics, Inc.
- Ticker ESPR
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—Specialty & Generic
- Shares Outstandng 66,551,600
- Market Cap $139M
- Description
- Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol. Its lead product candidates are NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets for the treatment of patients with atherosclerotic cardiovascul...